Shandong Keyuan Pharmaceutical Co., Ltd.

SZSE:301281 Stock Report

Market Cap: CN¥3.4b

Shandong Keyuan Pharmaceutical Past Earnings Performance

Past criteria checks 1/6

Shandong Keyuan Pharmaceutical has been growing earnings at an average annual rate of 7.8%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 7.5% per year. Shandong Keyuan Pharmaceutical's return on equity is 3.7%, and it has net margins of 11.5%.

Key information

7.8%

Earnings growth rate

3.4%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate7.5%
Return on equity3.7%
Net Margin11.5%
Last Earnings Update30 Sep 2024

Recent past performance updates

Shandong Keyuan Pharmaceutical's (SZSE:301281) Weak Earnings May Only Reveal A Part Of The Whole Picture

Apr 08
Shandong Keyuan Pharmaceutical's (SZSE:301281) Weak Earnings May Only Reveal A Part Of The Whole Picture

Recent updates

More Unpleasant Surprises Could Be In Store For Shandong Keyuan Pharmaceutical Co., Ltd.'s (SZSE:301281) Shares After Tumbling 27%

Apr 18
More Unpleasant Surprises Could Be In Store For Shandong Keyuan Pharmaceutical Co., Ltd.'s (SZSE:301281) Shares After Tumbling 27%

Shandong Keyuan Pharmaceutical's (SZSE:301281) Weak Earnings May Only Reveal A Part Of The Whole Picture

Apr 08
Shandong Keyuan Pharmaceutical's (SZSE:301281) Weak Earnings May Only Reveal A Part Of The Whole Picture

Revenue & Expenses Breakdown

How Shandong Keyuan Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SZSE:301281 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 244385010136
30 Jun 244606210344
31 Mar 244706610845
31 Dec 234487710044
30 Sep 23449899141
30 Jun 23443918532
31 Mar 23454966930
01 Jan 23443915727
01 Jan 22421786324
31 Dec 20367697128
31 Dec 19311306231
30 Sep 19301465517
30 Jun 19265532612
31 Mar 19261443411
31 Dec 18271205611
30 Sep 1826631468
30 Jun 1826034417
31 Mar 1824946290
31 Dec 1723944277
30 Sep 1721840265
30 Jun 1719636252
31 Mar 1718332270
31 Dec 1618033240
30 Sep 1616729240
30 Jun 1615525230
31 Mar 1613920210
31 Dec 1512314190
31 Dec 141339160
31 Dec 131331220

Quality Earnings: 301281 has a high level of non-cash earnings.

Growing Profit Margin: 301281's current net profit margins (11.5%) are lower than last year (19.8%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 301281's earnings have grown by 7.8% per year over the past 5 years.

Accelerating Growth: 301281's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 301281 had negative earnings growth (-43.6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.5%).


Return on Equity

High ROE: 301281's Return on Equity (3.7%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 12:33
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shandong Keyuan Pharmaceutical Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution